Congratulations to the winners of the OBN Awards

Congratulations to the winners of the OBN Awards

12 October 2018

Our clients GammaDelta Therapeutics and James Noble of Adaptimmune have both received awards at the OBN Annual Awards.

GammaDelta Therapeutics were awarded the Outstanding Achievement Award and James Noble, CEO of Adaptimmune and Deputy Chairman of GW Pharmaceuticals, was awarded the Special Recognition Award for his outstanding contribution to the UK life sciences industry.

Gamma Delta Therapeutics is a breakthrough immunotherapy company founded on pioneering research into gamma delta T cells. This research is used to develop improved immunotherapies for cancer and other serious immune related diseases. Led by Professor Adrian Hayday and Dr Oliver Nussbaumer at King’s College London and the Francis Crick Institute, they are also funded in part by Cancer Research UK.

Adaptimmune is a leader in T-cell therapy. The company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumours. James Noble is a co-founder of the firm with 27 years of experience in the biotech industry.

The OBN Awards, which are now in their 10th year, celebrate innovation and achievement in the life sciences industry.

Congratulations to both GammaDelta Therapeutics and James Noble of Adaptimmune! The full list of winners is available here.

Partner Emily Hayes works with GammaDelta Therapeutics and Partner Nick Sutcliffe works with Adaptimmune on their patent portfolios.